Metabolic control by liver-kidney crosstalk and glucagon in health and disease

More on GCGR

• The New England Journal of Medicine·4 Oct 2026

  Survodutide reduces weight in adults with diabetes and obesity

  

• Diabetes & Vascular Disease Research·4 Oct 2026

  SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

• Lancet·4 Oct 2026

  Retatrutide reduces bodyweight in obesity and type 2 diabetes

• Cell Metabolism·8 Oct 2026

  A triple-target drug cut body weight by up to 19.7% in a trial